1. Home
  2. H vs VTRS Comparison

H vs VTRS Comparison

Compare H & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hyatt Hotels Corporation

H

Hyatt Hotels Corporation

HOLD

Current Price

$170.22

Market Cap

15.4B

ML Signal

HOLD

Logo Viatris Inc.

VTRS

Viatris Inc.

HOLD

Current Price

$16.55

Market Cap

17.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
H
VTRS
Founded
1957
1961
Country
United States
United States
Employees
N/A
30000
Industry
Hotels/Resorts
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.4B
17.7B
IPO Year
2009
2019

Fundamental Metrics

Financial Performance
Metric
H
VTRS
Price
$170.22
$16.55
Analyst Decision
Buy
Buy
Analyst Count
15
4
Target Price
$179.53
$13.50
AVG Volume (30 Days)
711.1K
12.4M
Earning Date
04-30-2026
05-07-2026
Dividend Yield
0.38%
3.21%
EPS Growth
N/A
N/A
EPS
0.40
0.15
Revenue
$4,685,000,000.00
$14,299,900,000.00
Revenue This Year
$110.63
$4.41
Revenue Next Year
$7.01
$1.96
P/E Ratio
$421.63
$110.03
Revenue Growth
5.78
N/A
52 Week Low
$124.82
$8.19
52 Week High
$180.53
$17.53

Technical Indicators

Market Signals
Indicator
H
VTRS
Relative Strength Index (RSI) 58.92 63.17
Support Level $137.21 $9.82
Resistance Level $172.01 N/A
Average True Range (ATR) 5.31 0.57
MACD 0.03 0.06
Stochastic Oscillator 82.20 64.84

Price Performance

Historical Comparison
H
VTRS

About H Hyatt Hotels Corporation

Hyatt is an operator of owned (2% of total rooms) and managed and franchised (98%) properties across about 35 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva, and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, the wellness brand Miraval, and the midscale extended-stay brand Studios. Hyatt acquired Two Roads Hospitality in 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 45% for the US, 31% rest of world, and 24% Asia-Pacific.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: